Article Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitus

Authors: Constantine E. Kosmas, Andreas Sourlas, Kyriaki V. Bouza, Eddy DeJesus, Delia Silverio, Peter D. Montan, Eliscer Guzman


Cardiovascular disease (CVD) is the leading global cause of death and accounts for approximately 30% of the total annual deaths worldwide (1). In the United States, CVD is very common and affects over one third of the population (2). It is well established that low-density lipoprotein cholesterol (LDL-C) is involved in the pathogenesis of atherosclerosis, and treatment with LDLC- lowering medications has elicited a marked reduction in cardiovascular risk in both primary (3) and secondary (4) prevention.